Theravance Biopharma Statistics
Share Statistics
Theravance Biopharma has 49.17M shares outstanding. The number of shares has increased by -1.76% in one year.
| Shares Outstanding | 49.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.34M |
| Failed to Deliver (FTD) Shares | 2.04K |
| FTD / Avg. Volume | 1.04% |
Short Selling Information
The latest short interest is 4.92M, so 10.01% of the outstanding shares have been sold short.
| Short Interest | 4.92M |
| Short % of Shares Out | 10.01% |
| Short % of Float | 10.87% |
| Short Ratio (days to cover) | 31.5 |
Valuation Ratios
The PE ratio is -11.26 and the forward PE ratio is 167.67.
| PE Ratio | -11.26 |
| Forward PE | 167.67 |
| PS Ratio | 10.82 |
| Forward PS | 5.1 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -21.08 |
| PEG Ratio | n/a |
Enterprise Valuation
Theravance Biopharma Inc. has an Enterprise Value (EV) of 627.30M.
| EV / Earnings | -11.37 |
| EV / Sales | 10.92 |
| EV / EBITDA | -15.35 |
| EV / EBIT | -11.77 |
| EV / FCF | -21.28 |
Financial Position
The company has a current ratio of 5.39, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.39 |
| Quick Ratio | 5.39 |
| Debt / Equity | 0.23 |
| Total Debt / Capitalization | 18.75 |
| Cash Flow / Debt | -0.55 |
| Interest Coverage | -22.68 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -22.77%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -22.77% |
| Revenue Per Employee | 580.04K |
| Profits Per Employee | -557.51K |
| Employee Count | 99 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 5.92M |
| Effective Tax Rate | -0.12 |
Stock Price Statistics
The stock price has increased by -10.19% in the last 52 weeks. The beta is 0.25, so Theravance Biopharma 's price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -10.19% |
| 50-Day Moving Average | 9.02 |
| 200-Day Moving Average | 8.87 |
| Relative Strength Index (RSI) | 59.16 |
| Average Volume (20 Days) | 195.27K |
Income Statement
In the last 12 months, Theravance Biopharma had revenue of $57.42M and earned -$55.19M in profits. Earnings per share was $-1.
| Revenue | 57.42M |
| Gross Profit | 16.80M |
| Operating Income | -53.29M |
| Net Income | -55.19M |
| EBITDA | -40.87M |
| EBIT | -53.29M |
| Earnings Per Share (EPS) | -1 |
Balance Sheet
The company has $39.55M in cash and $49.16M in debt, giving a net cash position of -$9.61M.
| Cash & Cash Equivalents | 39.55M |
| Total Debt | 49.16M |
| Net Cash | -9.61M |
| Retained Earnings | -909.10M |
| Total Assets | 356.11M |
| Working Capital | 93.05M |
Cash Flow
In the last 12 months, operating cash flow was -$27.00M and capital expenditures -$2.49M, giving a free cash flow of -$29.48M.
| Operating Cash Flow | -27.00M |
| Capital Expenditures | -2.49M |
| Free Cash Flow | -29.48M |
| FCF Per Share | -0.53 |
Margins
Gross margin is 29.26%, with operating and profit margins of -92.8% and -96.11%.
| Gross Margin | 29.26% |
| Operating Margin | -92.8% |
| Pretax Margin | -85.8% |
| Profit Margin | -96.11% |
| EBITDA Margin | -71.17% |
| EBIT Margin | -92.8% |
| FCF Margin | -51.35% |
Dividends & Yields
TBPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.13% |
| FCF Yield | -6.07% |
Analyst Forecast
The average price target for TBPH is $12.5, which is 26.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.5 |
| Price Target Difference | 26.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -1.89 |
| Piotroski F-Score | 5 |